Professional paper

Contemporary management of hypertension with telmisartan

Aleša Primožič ; Krka, d. d., Novo mesto, Slovenia
Polona Knavs-Vrhunec ; Krka, d. d., Novo mesto, Slovenia
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia

Abstract

Telmisartan is long-acting, potent, highly selective angiotensin II subtype 1 (AT1) receptor antagonist. It provides a more specific and complete blockade of the actions of angiotensin II than ACE inhibitors. Telmisartan has already been established as an effective once- daily blood-pressure-lowering drug in different types of patients. It is a well-tolerated and effective antihypertensive therapy, which offers full 24 h control of blood pressure even in the event of a missed dose. Nevertheless that the efficacy of angiotensin receptor blockers (ARBs) in different type of patients were confirmed, telmisartan is currently the only ARB with clear evidence and indication for usage in cardiovascular event risk reduction.

Keywords

telmisartan; hypertension; blood pressure; angiotensin receptor antagonist; cardiovascular disease

Hrčak ID:

112567

URI

https://hrcak.srce.hr/112567

Publication date:

2.10.2013.

Article data in other languages: croatian

Visits: 1.150 *